# Appendix 1 Search strategy

Database	Search terms	No. of studies generated					
PubMed	<ul> <li>#1 (Lung Neoplasms[MeSH Terms]) OR (Neoplasm, Lung[Title/Abstract])) OR (Neoplasms, Pulmonary[Title/Abstract])) OR (Pulmonary Neoplasm[Title/Abstract])) OR (Lung Cancers[Title/Abstract] OR Cancer, Pulmonary[Title/Abstract])) OR (Pulmonary Cancers[Title/Abstract])) OR (Cancer of Lung[Title/Abstract])</li> <li>#2 (Volatile Organic Compounds[MeSH Terms])) OR (Organic Compound, Volatile[Title/Abstract])) OR (VOCs[Title/Abstract])) OR (Volatile organic breath components[Title/Abstract])</li> <li>#3 (exhaled) OR (breath)</li> <li>#4 #1 AND #2 AND #3</li> </ul>						
Embase	#1 'lung tumor'/exp #2 'lung tumor':ab,ti OR 'broncho-pulmonary neoplasm':ab,ti OR 'broncho-pulmonary tumo':ab,ti OR 'broncho-pulmonary neoplasm':ab,ti OR 'bronchopulmonary tumor':ab,ti OR 'lung neoplasia':ab,ti OR 'lung neoplasm':ab,ti OR 'lung tumori:ab,ti OR 'lung tumour':ab,ti OR 'neoplasia':ab,ti OR 'neoplasia':ab,ti OR 'neoplasia':ab,ti OR 'pulmonary neoplasia':ab,ti OR 'pulmonary neoplasia':ab,ti OR 'pulmonary tumori:ab,ti OR 'tumor of the lung':ab,ti OR 'tumor, lung':ab,ti OR 'tumorigenesis in the lung':ab,ti OR 'tumor, lung':ab,ti I 'ab,ti OR 'organic compound, volatile':ab,ti OR 'volatile organic compound':ab,ti I oR 'organic compound, volatile':ab,ti OR 'volatile organic compound':ab,ti I OR 'at the state of the lung 'ab,ti I oR 'state organic compound':ab,ti I oR 'organic compound, volatile':ab,ti I oR 'volatile organic compound':ab,ti I oR 'state organic compound':ab,ti I oR 'organic compound, volatile':ab,ti I oR 'volatile organic compound':ab,ti I oR 'state organic compound':ab,ti I oR 'organic compound, volatile':ab,ti I oR 'volatile organic compound':ab,ti I oR 'state organic compound':ab,ti I oR 'state organic compound':ab,ti I oR 'state organic compound':ab,ti I oR 'volatile organic compound':ab,ti I oR 'state organic compound':ab,ti I oR 'volatile organic compound	569					
Web of Science	<ul> <li>#1 ((TS=(Volatile Organic Compounds) OR AB=(Organic Compound, Volatile OR VOCs OR Volatile organic breath components))</li> <li>#2 (TS=(Lung Neoplasms) OR AB=(Neoplasm, Lung OR Neoplasms, Pulmonary OR Pulmonary Neoplasm OR Lung Cancers OR Cancer, Pulmonary OR Pulmonary Cancers OR Cancer of Lung))</li> <li>#3 (TS=(exhaled OR breath))</li> <li>#4 #1 AND #2 AND #3</li> </ul>	698					
Cochrane Library	<ul> <li>#1 MeSH descriptor: [Lung Neoplasms] explode all trees</li> <li>#2(Neoplasm, Lung OR Neoplasms, Pulmonary OR Pulmonary Neoplasm OR Lung Cancers OR Cancer, Pulmonary OR Pulmonary Cancers OR Cancer of Lung):ti,ab,kw</li> <li>#3 #1 AND #2</li> <li>#4 MeSH descriptor: [Volatile Organic Compounds] explode all trees</li> <li>#5(Organic Compound, Volatile OR VOCs OR Volatile organic breath components):ti,ab,kw</li> <li>#6 #4 AND #5</li> <li>#7 #3 AND #6</li> </ul>	7					

Appendix 2 Details of participants and the Newcastle-Ottawa Quality Assessment Scale scores in the included studies

## Details of participants

Study		- Analysis Platform					
	Patients With Lung Cancer, No.	Cancer Stage	Smoker In Cancer	Smoker In Control	Groups	Setting	
Phillips <i>et al.</i> , 1999 (1)	60	I-IV or unknown	NR	NR	LC, HC	USA	GC-MS
/u et al., 2005 (2)	15	II-IV	9	0	LC, HC	China	GC-MS
Phillips <i>et al.</i> , 2007 (3)	193	Mixed	33	78	LC, HC	USA	GC-MS
<i>W</i> ehinger <i>et al.</i> , 2007 (4)	17	I-V	9	60	LC, HC	Austria	PTR-MS
Phillips <i>et al.</i> , 2008 (5)	193	Mixed	NR	NR	LC, HC	USA	GC-MS
Bajtarevic <i>et al.</i> , 2009 (6)	285	NR	68	84	LC, HC	NR	PTR-MS, GC-MS
Gaspar <i>et al.</i> , 2009 (7)	18	NR	NR	NR	LC, HC	Portugal	GC-MS
igor <i>et al.</i> , 2009 (8)	65	NR	28	7	LC, HC	Austria	GC-MS
Peng <i>et al.</i> , 2009 (9)	40	III-IV	0	17	LC, HC	Israel	GC-MS
Vesthoff <i>et al.</i> , 2009 (10)	32	0-IV	7	12	LC, HC	Germany	IMS
Fuchs <i>et al.</i> , 2010 (11)	12	>T3	0	0	LC, HC	Germany	GC-MS
Poli <i>et al.</i> , 2010 (12)	40	1-111	21	0	LC, HC	Italy	GC-MS
Kischkel <i>et al.</i> , 2010 (13)	31	>T2	0	4	LC, HC	Germany	GC-MS
Song <i>et al.</i> , 2010 (14)	43	I-IV	0	0	LC, HC	China	GC-MS
ran <i>et al.</i> , 2010 (15)	16	NR	16	18	LC, HC	China	Electronic Nose
Buszewski <i>et al.</i> , 2011 (16)	115	NR	NR	NR	LC, HC	Poland	GC-MS
Rudnicka <i>et al.</i> , 2011 (17)	23	NR	21	6	LC, HC	Poland	GC-TOF/MS
Jlanowska <i>et al.</i> , 2011 (18)	137	NR	NR	57	LC, HC	Poland	GC-MS
3uszewski <i>et al.</i> , 2012 (19)	29	NR	NR	NR	LC, HC	Poland	GC-TOF/MS
Filipiak <i>et al.</i> , 2014 (20)	36	I-IV	NR	NR	LC, HC	Austria	GC-MS
Gi <i>et al.</i> , 2014 (21)	NR	NR	NR	NR	LC, HC	Korea	GC-MS
Ma et al., 2014 (22)	13	III-IV	5	16	LC, HC	China	NR
Phillips <i>et al.</i> , 2015 (23)	172	NR	NR	0	LC, HC	USA	GC-MS
igor <i>et al.</i> , 2015 (24)	123	III-IV	109	11	LC, HC	Austria	GC-MS
Gasparri <i>et al.</i> , 2016 (25)	70	I-IV	27	31	LC, HC	Italy	Electronic Nose
toh <i>et al.</i> , 2016 (26)	107	I-IV	NR	NR	LC, HC	Japan	GC-MS
Sakumura <i>et al.</i> , 2017 (27)	107	I-IV	47	5	LC, HC	Japan	GC-MS
Cai, <i>et al.</i> , 2017 (28)	57	NR	22	25	LC, HC	China	Electronic Nose
Chang <i>et al.</i> , 2018 (29)	37	I-IV	9	4	LC, HC	Korea	Metal oxide gas sensor
luang <i>et al.,</i> 2018 (30)	56	I-IV	2	25	LC, HC	China	Electronic Nose
Yu <i>et al.</i> , 2018 (31)	6	NR	NR	NR	LC, HC	China	NR
_i <i>et al.</i> , 2019 (32)	389	NR	NR	NR	LC, HC	China	GC-MS

Appendix 2 (continued)

Study			Information	of patients			Analysis Platform	
olddy	Patients With Lung Cancer, No.	Cancer Stage Smoker In Car		Smoker In Control	Groups	Setting	Analysis Flationn	
Pesesse <i>et al.</i> , 2019 (33)	15	NR	3	1	LC, HC	Belgium	$TD\text{-}GC\timesGC\text{-}TOFMS$	
Rudnicka <i>et al.</i> , 2019 (34)	108	I-IV	49	13	LC, HC	Poland	GC-MS	
Chen <i>et al.</i> , 2020 (35)	48	NR	NR	NR	LC, HC	China	Electronic Nose	
Gashimova <i>et al.</i> , 2020 (36)	75	T1-T4	25	12	LC, HC	Russia	GC-MS	
Koureas <i>et al.</i> , 2020 (37)	51	NR	8	20	LC, HC	Greece	GC-MS	
i <i>et al.</i> , 2020 (38)	115	NR	NR	10	LC, HC	China	Electronic Nose	
Saidi <i>et al.</i> , 2020 (39)	32	NR	2	3	LC, HC	Morocco	GC/QTOF/MS, Electronic Nos	
Chen <i>et al.</i> , 2021 (40)	90	III, IV	63	75	LC, HC	China	Electronic Nose	
Gashimova <i>et al.</i> , 2021 (41)	40	T1-T4	7	7	LC, HC	Russia	GC-MS, Electronic Nose	
Koureas <i>et al.</i> , 2021 (42)	49	NR	NR	NR	LC, HC	Greece	GC-MS	
.ee <i>et al.</i> , 2021 (43)	31	Mixed	NR	NR	LC, HC	Korea	Electronic Nose	
i <i>et al.</i> , 2021 (44)	6	NR	NR	NR	LC, HC	China	Q-TOF-MS	
iu <i>et al.</i> , 2021 (45)	46	NR	27	11	LC, HC	China	Electronic Nose	
iu <i>et al.</i> , 2021 (46)	102	NR	NR	NR	LC, HC	China	Electronic Nose	
ong <i>et al.</i> , 2021 (47)	116	I-IV	100	106	LC, HC	China	GC-MS	
(ia e <i>t al.</i> , 2021 (48)	10	NR	NR	NR	LC, HC	China	NR	
ou <i>et al.</i> , 2021 (49)	60	I-IV	32	112	LC, HC	China	GC-MS	
īsou <i>et al.</i> , 2021 (50)	148	I-IV	9	0	LC, HC	China	SIFT-MS	
Gashimova <i>et al.</i> , 2022 (51)	110	T1-T4	22	127	LC, HC	Russia	GC-MS	
arracy <i>et al.</i> , 2022 (52)	62	NR	12	6	LC, HC	Canada	CRDS	
Vang et al., 2022 (53)	157	1-111	12	NR	LC, HC	China	HPPI-TOFMS	
lao <i>et al</i> ., 2023 (54)	6	NR	NR	NR	LC, HC	China	GC-MS	
emerdashev <i>et al.</i> , 2023 (55)	112	I-IV	22	17	LC, HC	Russia	GC-MS	
i <i>et al.</i> , 2017 (56)	24	NR	19	4, 10	LC, PD, HC	China	Electronic Nose	
Chen <i>et al.</i> , 2005 (57)	20	NR	NR	NR	LC, CB, HC	China	Electronic Nose	
Poli <i>et al.</i> , 2005 (58)	36	1-11	2	1, 0	LC, COPD, HC	Italy	GC-MS	
<i>l</i> azzone <i>et al.</i> , 2007 (59)	49	I-IV	27	6, 0, 5, 0, 14	LC, COPD, IPF, PAH, S, HC	USA	Colorimetric sensor array	
0ragonieri <i>et al.</i> , 2009 (60)	10	1-111	2	6, 0	LC, COPD, HC	The Netherlands	Electronic Nose	
<sup>o</sup> 'Amico <i>et al.</i> , 2010 (61)	28	NR	NR	NR	LC, PD, HC	Italy	GC-MS	
lazzone <i>et al.</i> , 2012 (62)	92	I-IV	25	28	LC, RLC	USA	Colorimetric sensor array	
Santonico <i>et al.</i> , 2012 (63)	20	NR	7	NR	LC, BTS	Italy	Electronic Nose	
Nang et al., 2012 (64)	88	I-IV	55	35, 41	LC, BPD, HC	China	GC-MS	
Broza <i>et al.</i> , 2013 (65)	12	1-11	5	2	LC, BPD	Israel	GC-MS	

Appendix 2 (continued)

Ctudy.		- Analysis Platform					
Study	Patients With Lung Cancer, No.	Cancer Stage	Smoker In Cancer	Smoker In Control	Groups	Setting	- Analysis Platform
Bousamra <i>et al.</i> , 2014 (66)	107	0, I, or II	44	12, 45	LC, BPD, HC	NR	NR
Fu <i>et al.</i> , 2014 (67)	97	I-IV	NR	NR	LC, BPN, HC	USA	NR
Zou et al., 2014 (68)	79	I-IV	15	12, 9	LC, BPD, HC	China	GC-MS
Capuano <i>et al.</i> , 2015 (69)	20	NR	6	5	LC, PD	Italy	GC-MS, Electronic Nose
Li <i>et al.</i> , 2015 (70)	85	I-IV or unknown	45	10, 45	LC, BPN, HC	USA	FT-ICR-MS
Schumer <i>et al.</i> , 2015 (71)	156	0-IV	69	25, 73	LC, BPN, HC	USA	Silicon chip-MS
Tan <i>et al.</i> , 2016 (72)	12	II-IV	2	1, 0	LC, COPD, HC	Malaysia	Alkane sensor
Callol-Sanchez <i>et al.</i> , 2017 (73)	) 81	I-IV	50	34, 30	LC, COPD, HC	Spain	TD-GC-MS
Kistenev <i>et al.</i> , 2017 (74)	9	T2-T4	8	10	LC, COPD, HC	Russia	NR
Shlomi <i>et al.</i> , 2017 (75)	89	I-IV	72	24	LC, BPN	Israel	Electronic Nose
Nang <i>et al.</i> , 2018 (76)	233	NR	102	41, 69	LC, BPD, HC	China	GC-MS
Zuo <i>et al.</i> , 2019 (77)	41	≥IIIA	23	5, 18	LC, LI, HC	China	EESI-MS
Binson <i>et al.</i> , 2021 (78)	40	I-IV	0	28, 10	LC, COPD, HC	India	Electronic Nose
Binson <i>et al.</i> , 2021 (79)	51	NR	4	8, 3	LC, COPD, HC	India	Electronic Nose
Binson <i>et al.</i> , 2021 (80)	32	NR	3	6, 33	LC, COPD, HC	India	Electronic Nose
Binson <i>et al.</i> , 2021 (81)	48	I-IV	1	4, 10, 21	LC, COPD, Asthma, HC	India	Electronic Nose
Chen <i>et al.</i> , 2021 (82)	160	I-IV	33	12, 73	LC, BPN, HC	China	TD-GC-MS
Marzorati <i>et al.</i> , 2021 (83)	40	1-111	14	21	LC, RLC	Italy	Electronic Nose
Monedeiro <i>et al.</i> , 2021 (84)	16	NR	3	2, 2	LC, COPD, HC	Poland	GC-MS
Zhao e <i>t al.</i> , 2021 (85)	84	NR	NR	NR	LC, COPD, HC	China	Electronic Nose
Rai <i>et al.</i> , 2022 (86)	156	0-11	149	113	LC, BPN, HC	USA	FT-ICR-MS
Nei et al., 2022 (87)	92	NR	45	5, 5	LC, BPD, HC	China	CRDS
Smirnova <i>et al.</i> , 2022 (88)	88	I	NR	NR	LC, BPD	USA	GC-MS
Ding <i>et al.</i> , 2023 (89)	88	1-111	0	0	LC, BPN	China	HPPI-TOFMS

References are showed in Appendix 5. LC: lung cancer, HC: healthy control, BPN: benign pulmonary nodules, USA: United States of America, COPD: chronic obstructive pulmonary disease, S: sarcoidosis, RLC: have a risk for developing lung cancer, BPD: benign pulmonary disease, LI: lung infection, PD: pulmonary disease, BTS: benign tracheal stenosis, CB: chronic bronchitis, IPF: idiopathic pulmonary fibrosis, PAH: pulmonary arterial hypertension, NR: not report, MS: mass spectrometry; GC-MS: gas chromatography-mass spectrometry, PTR-MS: proton transfer reaction mass spectrometry, IMS: ion mobility spectrometry, Q-TOF-MS: quadrupole time-of-flight mass spectrometry, TD-GC-MS: thermal desorption-gas chromatography-mass spectrometry, SIFT-MS: selected ion flow tube-mass spectrometry, FT-ICR-MS: fourier transform ion cyclotron resonance mass spectrometry, CRDS: cavity ringdown spectroscopy, EESI-MS: extractive electrospray extraction ionization mass spectrometry, HPPI-TOFMS: high-pressure photon ionization time-of-flight mass spectrometry; GC-TOF/MS: gas chromatography-time of flight mass spectrometry; TD-GC × GC-TOFMS: thermal desorption-comprehensive two-dimensional gas chromatography-time of flight mass spectrometry; GC/QTOF/MS: gas chromatography-quadrupole-time of flight mass spectrometry.

Appendix 2 (continued)

		Se	election		Outcome			
Study	Representativeness of the sample	Sample size	Non-respondents	Ascertainment of the exposure (risk factor)	Comparability	Assessment of the outcome	Statistical test	Score
Bajtarevic <i>et al.</i> , 2009 (6)	*	*	*	*	*	*	*	7
Binson <i>et al.</i> , 2021 (78)	*		*	*	**	*		6
Binson <i>et al.</i> , 2021 (79)	*		*	*	*	*	*	6
Binson <i>et al.</i> , 2021 (80)	*		*	*	*	*	*	6
Binson <i>et al.</i> , 2021 (81)	*		*	*	**	*	*	7
Bousamra et al., 2014 (66)	*	*	*	**	*	*	*	8
Broza et al., 2013 (65)	*	*	*	*	*	*	*	7
Buszewski <i>et al.</i> , 2012 (19)	*		*	*	*	*	*	6
Buszewski <i>et al.</i> , 2011 (16)	*	*	*	*	*	*	*	7
Cai, <i>et al.</i> , 2017 (28)	*		*	*	*	*	*	6
Callol-Sanchez et al., 2017 (73)	*	*	*	*	*	*	*	7
Capuano <i>et al.</i> , 2015 (69)	*		*	*	*	*	*	6
Chang et al., 2018 (29)	*	*		*	*	*	*	6
Chen <i>et al.</i> , 2021 (40)	*	*	*	**	**	*	*	9
Chen <i>et al.</i> , 2020 (35)	*		*	*	*	*	*	6
Chen <i>et al.</i> , 2005 (57)	*		*	*	*	*	*	6
Chen <i>et al.</i> , 2021 (82)	*	*	*	*	**	*	*	8
D'Amico <i>et al.</i> , 2010 (61)	*	*	*	*	*	*	*	7
Ding et al.,2023 (89)	*	*	*	*	**	*	*	8
Dragonieri <i>et al.</i> , 2009 (60)	*	*	*	*	*	*	*	7
Filipiak <i>et al.</i> , 2014 (20)	*		*		*	*	*	5
Fu et al., 2014 (67)	*	*	*	*	*	*	*	7
Fuchs <i>et al.</i> , 2010 (11)	*	*	*	**	*	*	*	8
Gashimova <i>et al.</i> , 2020 (36)	*	*	*	*	*	*	*	7
Gashimova <i>et al.</i> , 2021 (41)	*		*	*	*	*	*	6
Gashimova <i>et al.</i> , 2022 (51)	*	*	*	*	**	*	*	8
Gaspar <i>et al.</i> , 2009 (7)	*		*	*	*	*	*	6
Gasparri <i>et al.</i> , 2016 (25)	*	*	*	*	*	*	*	7
Gi e <i>t al.</i> , 2014 (21)	*		*	*	*		*	5
Hao <i>et al.</i> , 2023 (54)	*		*	*	*	*	*	6
Huang <i>et al.</i> , 2018 (30)	*	*	*	**	*	*	*	8
ltoh <i>et al.</i> , 2016 (26)	*	*	*	*	*	*	*	7
Kischkel <i>et al.</i> , 2010 (13)	*		*	*	*	*	*	6

# The Newcastle-Ottawa Quality Assessment Scale scores in the included studies

(continued)

(continued)

		election		Outcome				
Study	Representativeness of the sample	Sample size	Non-respondents	Ascertainment of the exposure (risk factor)	Comparability	Assessment of the outcome	Statistical test	Score
Kistenev et al., 2017 (74)	*		*	*	*	*	*	6
Koureas et al., 2021 (42)	*		*	*	*	*	*	6
Koureas <i>et al.</i> , 2020 (37)	*	*	*	*	*	*	*	7
Larracy et al., 2022 (52)	*	*	*	*	*		*	6
Lee et al., 2021 (43)	*		*	**	*	*	*	7
Li <i>et al.</i> , 2015 (70)	*	*	*	**	*	*	*	8
Li <i>et al.</i> , 2019 (32)	*	*	*	**	**	*	*	9
Li <i>et al.</i> , 2020 (38)	*	*	*	*	**	*	*	8
Li et al., 2021 (44)	*			*	*	*	*	5
Ligor <i>et al.</i> , 2009 (8)	*		*	*	*	*	*	6
Ligor et al., 2015 (24)	*	*	*	*	*	*	*	7
Liu <i>et al.</i> , 2021 (45)	*		*	**	*	*	*	7
Liu <i>et al.</i> , 2021 (46)	*	*	*	*	*	*	*	7
Long et al., 2021 (47)	*	*	*	*	**	*	*	8
Ma et al., 2014 (22)	*		*	*	*	*	*	6
Marzorati et al., 2021 (83)	*		*	**	*	*	*	7
Mazzone <i>et al.</i> , 2007 (59)	*		*	*	*	*	*	6
Mazzone <i>et al.</i> , 2012 (62)	*	*	*	*	*	*	*	7
Monedeiro <i>et al.</i> , 2021 (84)	*		*	*	*	*	*	6
Peng <i>et al.</i> , 2009 (9)	*		*	*	*	*	*	6
Pesesse et al., 2019 (33)	*	*	*	*	*	**	*	8
Phillips <i>et al.</i> , 1999 (1)	*		*	**	*	*	*	7
Phillips <i>et al.</i> , 2007 (3)	*	*	*	*	**	*	*	8
Phillips <i>et al.</i> , 2008 (5)	*	*	*	*	*	**	*	8
Poli <i>et al.</i> , 2005 (58)	*		*	*	*	*	*	6
Poli <i>et al.</i> , 2010 (12)	*		*	**	*	*	*	7
Rai <i>et al.</i> , 2022 (86)	*	*	*	**	*	*	*	8
Rudnicka <i>et al.</i> , 2019 (34)	*	*	*	*	*	*	*	7
Rudnicka <i>et al.</i> , 2011 (17)	*	*	*	*	*	*	*	7
Saidi <i>et al.</i> , 2020 (39)	*		*	**	*	**	*	8
Sakumura <i>et al.</i> , 2017 (27)	*	*	*	*	*	*	*	7
Santonico et al., 2012 (63)	*		*	*	*	*	*	6

(continued)

(continued)

		Se	election		Outcome			
Study	Representativeness of the sample	Sample size	Non-respondents	Ascertainment of the exposure (risk factor)	Comparability	Assessment of the outcome	Statistical test	Score
Schumer et al., 2015 (71)	*	*	*	*	*	*	*	7
Shlomi <i>et al.</i> , 2017 (75)	*	*	*	**	*		*	7
Smirnova <i>et al.</i> , 2022 (88)	*	*	*	**	*	*	*	8
Song et al., 2010 (14)	*		*	*	**	*	*	7
Tan <i>et al.</i> , 2016 (72)	*		*	*	*	*	*	6
Temerdashev et al., 2023 (55)	*	*	*	**	*	*	*	8
Tran et al., 2010 (15)	*		*	*	*	*	*	6
Tsou <i>et al.</i> , 2021 (50)	*	*	*	**	*		*	7
Ulanowska <i>et al.</i> , 2011 (18)	*	*		**	*	*	*	7
Wang et al., 2018 (76)	*	*		*	*	*	*	6
Wang et al., 2022 (53)	*	*	*	*	**	*	*	8
Wang et al., 2012 (64)	*	*	*	*	*	*	*	7
Wehinger <i>et al.</i> , 2007 (4)	*	*	*	**	*		*	7
Wei <i>et al.</i> , 2022 (87)	*	*	*	*		*	*	6
Westhoff et al., 2009 (10)			*	*	*	*	*	5
Xia et al., 2021 (48)	*		*	*	*	*	*	6
Yu <i>et al.</i> , 2018 (31)	*		*	*	*	*	*	6
Yu <i>et al.</i> , 2005 (2)	*	*	*	*	*	*	*	7
Zhao et al., 2021 (85)		*	*	*	*	*	*	6
Zou <i>et al.</i> , 2021 (49)	*	*	*	**	*	*	*	8
Zou <i>et al.</i> , 2014 (68)	*	*	*	**	*	*	*	8
Zuo et al., 2019 (77)	*		*	*	*	*		5
Phillips et al., 2015 (23)	*	*	*	**	*	*	*	8
Li <i>et al.</i> , 2017 (56)	*		*	*	*	*	*	6

References are showed in Appendix 5.

Appendix 3 Newcastle-Ottawa Quality Assessment Scale

(Adapted for cross-sectional studies)

Selection: (Maximum 5 stars)

1) Representativeness of the sample:

a) Truly representative of the average in the target population. \* (all subjects or random sampling)

b) Somewhat representative of the average in the target population. \* (non-random sampling)

c) Selected group of users.

d) No description of the sampling strategy.

2) Sample size:

a) Justified and satisfactory. \*

b) Not justified.

3) Non-respondents:

a) Comparability between respondents and non-respondents characteristics is established, and the response rate is satisfactory. \*

b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is unsatisfactory.

c) No description of the response rate or the characteristics of the responders and the non-responders.

4) Ascertainment of the exposure (risk factor):

a) Validated measurement tool. \*\*

b) Non-validated measurement tool, but the tool is available or described.\*

c) No description of the measurement tool.

Comparability: (Maximum 2 stars)

1) The subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled.

a) The study controls for the most important factor (select one). \*

b) The study control for any additional factor. \*

Outcome: (Maximum 3 stars)

1) Assessment of the outcome:

a) Independent blind assessment. \*\*

b) Record linkage. \*\*

c) Self report. \*

d) No description.

2) Statistical test:

a) The statistical test used to analyze the data is clearly described and appropriate, and the measurement of the association is presented, including confidence intervals and the probability level (p value). \*

b) The statistical test is not appropriate, not described or incomplete.

#### Appendix 4 171 articles excluded after the full-text review

No.	Study, year	Main reason	Citations
1	Poli, 2008	Not published in full-text	Poli D, Goldoni M, Caglieri A, et al. Breath analysis in non small cell lung cancer patients after surgical tumour resection. Acta bio-medica : Atenei F
2	Umin, 2011	Not published in full-text	Umin. Ion Mobility Spectrometry in healthy and respiratory disease subjects. 2011
3	Umin, 2012	Not published in full-text	Umin. Detection of histological type and genetic mutation in lung cancer using ion mobility spectrometry. 2012
4	Ho, 2014	Not published in full-text	Ho KC, Seungho L, Kim D, et al. Preparation and characterization of the primary gas standards for isoprene. J Anal Sci Technol 2014;27:357-63
5	Mgwenya, 2018	Not published in full-text	Mgwenya TNZ. Polymer Nanocomposites-Based Sensors for the Detection of Lung Cancer Volatile Organic Biomarkers. 2018
6	Schallschmidt, 2015	Duplicate article	Schallschmidt K, Becker R, Zwaka H, et al. In vitro cultured lung cancer cells are not suitable for animal-based breath biomarker detection. J Breat
7	Bianchi, 2017	Duplicate article	Bianchi F, Riboni N, Carbognani P, et al. Solid-phase microextraction coupled to gas chromatography-mass spectrometry followed by multivariate Biomed Anal 2017;146:329-33
8	Cao, 2008	Articles published not in English	Cao MF, Chen X, Wang YQ, et al. A novel electronic nose for detection of lung cancer based on virtual SAW gas sensors array. Chin J Biomed Eng
9	Liu, 2009	Articles published not in English	Liu H, Song G, Qin T, et al. Quantitative analysis of volatile biomarkers in breath of non-small cell lung cancer patients. Chin J Cancer Prev Treat 20
10	Lu, 2010	Articles published not in English	Lu CR, Hu YJ, Chen EG, et al. Measurement of exhaled volatile organic compounds in lung cancer patients. Chin J Res Dis 2010;33:104-8
11	Valera, 2012	Articles published not in English	Valera JL, Togores B, Cosio BG. Use of the Electronic Nose for Diagnosing Respiratory Diseases. Archivos de Bronconeumologia 2012;48:187-8
12	Chen, 2015	Articles published not in English	Chen L, Liu C, Kang T, et al. Prediction model of volatile organic compounds in exhaled breath for diagnosis of lung cancer. Tumor 2015;35:404-13
13	Zhang, 2018	Articles published not in English	Zhang N, Sun Q, Li W, et al. Detection of volatile organic compounds in exhaled breath for early diagnosis of lung cancer. Tumor 2018;38:874-82
14	Matsumura, 2010	Animals experiment	Matsumura K, Opiekun M, Oka H, et al. Urinary Volatile Compounds as Biomarkers for Lung Cancer: A Proof of Principle Study Using Odor Signati
15	Hanai, 2013	Animals experiment	Hanai Y, Baba Y. Pretreatment Methods for Selections Lung Cancer Markers in Mouse Urine. Bunseki Kagaku 2013;62:437-42
16	Fu, 2020	Animals experiment	Fu JH, Zhong Z, Xie D, et al. SERS-Active MIL-100(Fe) Sensory Array for Ultrasensitive and Multiplex Detection of VOCs. Angewandte Chemie (Internet of VOCs) An
17	Chen, 2005	Review, meta, letter, comment or conference abstract	Chen X, Cao M, Hao Y, et al. A Non-invasive detection of lung cancer combined virtual gas sensors array with imaging recognition technique. Conf Engineering in Medicine and Biology Society Annual Conference 2005;2005:5873-6
18	Belda-Iniesta, 2007	Review, meta, letter, comment or conference abstract	Belda-Iniesta C, de Castro Carpeno J, Carrasco JA, et al. New screening method for lung cancer by detecting volatile organic compounds in breat
19	Mazzone, 2008	Review, meta, letter, comment or conference abstract	Mazzone PJ. Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer. J Thorac Oncol 2008;3:774-80
20	Lewis, 2009	Review, meta, letter, comment or conference abstract	Lewis KE, Philips CO, Shukla H, et al. Differences in profiles of volatile organic compounds in the breath of lung cancer patients vs controls. Thoras
21	Sponring, 2009	Review, meta, letter, comment or conference abstract	Sponring A, Filipiak W, Mikoviny T, et al. The release and uptake of volatile organic compounds (VOCs) from different lung cancer cell lines in vitro.
22	Filipiak, 2010	Review, meta, letter, comment or conference abstract	Filipiak W, Filipiak A, Bajtarevic A, et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer and healthy vol
23	Hu, 2010	Review, meta, letter, comment or conference abstract	Hu YJ, Qiu YH, Chen EG, et al. Determination of volatile organic compounds in lung cancer cell lines and lung cancer tissue. J Zhejiang Univ Med
24	Darwiche, 2011	Review, meta, letter, comment or conference abstract	Darwiche K, Kurth I, Baumbach JI, et al. Volatile organic compounds in lung cancer patients before and after tumour resection. Eur Respir J 2011;3
25	Hu, 2011	Review, meta, letter, comment or conference abstract	Hu Y, Ying K, Chen E, et al. The research on early detection of lung cancer with exhaled volatile organic compounds. Eur Respir J 2011;38
26	Jareño, 2011	Review, meta, letter, comment or conference abstract	Jareño J, Muñoz MA, Rodríguez G, et al. New contributions in the determination of volatile organic compounds (VOC) in lung cancer (LC). Eur Resp
27	Kurth, 2011	Review, meta, letter, comment or conference abstract	Kurth JI, Darwiche K, Baumbach JI, et al. A new possibility of process monitoring in lung cancer: Volatile organic compounds detected with ion mo
28	Kurth, 2011	Review, meta, letter, comment or conference abstract	Kurth JI, Darwiche K, Theegarten D, et al. A step towards easier diagnosis of lung cancer: Detection of volatile organic compounds in air releasing
29	Macaulay, 2011	Review, meta, letter, comment or conference abstract	Macaulay CE, Lam S, McWilliams AM. Detecting lung cancer from volatile organic compounds with an electronicnose (E-nose). J Thorac Oncol 20
30	Nick, 2011	Review, meta, letter, comment or conference abstract	Nick A, Stone R, Bottsford-Miller J, et al. Stop and smell the volatile organic compounds: A novel breath-based bioassay for detection of ovarian c
31	Esteban, 2012	Review, meta, letter, comment or conference abstract	Esteban JJ, Lucas MAM, Aranda BC, et al. Volatile organic compounds (VOC) in exhaled breath in patients with lung cancer, using the analytical te
32	Hakim, 2012	Review, meta, letter, comment or conference abstract	Hakim M, Broza YY, Barash O, et al. Volatile Organic Compounds of Lung Cancer and Possible Biochemical Pathways. Chem Rev 2012;112:5949-
33	Barash, 2013	Review, meta, letter, comment or conference abstract	Barash O, Tisch U, Haick H. Volatile organic compounds and the potential for a lung cancer breath test. Lung Cancer Manag 2013;2:471-82
34	Buszewski, 2013	Review, meta, letter, comment or conference abstract	Buszewski B, Grzywinski D, Ligor T, et al. Detection of volatile organic compounds as biomarkers in breath analysis by different analytical techniqu

Appendix 4 (continued)

tenei Parmensis 2008;79 Suppl 1:64-72

Breath Res 2015;9:027103 ariate data analysis for the identification of volatile organic compounds as possible biomarkers in lung cancer tissues. J Pharm

Eng 2008;27:102-7

reat 2009;16:1857-9

404-13

Signatures in Mouse Models of Lung Cancer. PLoS One 2010;5

nie (International ed in English) 2020;59:20489-98

e. Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE

breath. Clin Transl Oncol 2007;9:364-8

Thorax 2009;64:A60 vitro. Pteridines 2009;20:38 thy volunteers using TD-GCMS and PTR-MS. Pteridines 2010;21:36-7 Med Sci 2010;39:278-84 2011;38

<sup>•</sup> Respir J 2011;38

ion mobility spectrometry to follow the success of the therapeutic process. Eur Respir J 2011;38

asing tumour samples with ion-and differential mobility spectrometry. Eur Respir J 2011;38

col 2011;6:S513-S4

arian cancer. Gynecol Oncol 2011;120:S54-S5

tical technique thermal desorber-gase chromatography-spectrometer mases. Eur Respir J 2012;40 5949-66

chniques. Bioanalysis 2013;5:2287-306

Appendix	<b>4</b> (continued	D
----------	---------------------	---

No.	Study, year	Main reason	Citations
35	Munoz-Lucas, 2013	Review, meta, letter, comment or conference abstract	Munoz-Lucas A, Wagner-Struwing C, Jareno-Esteban J, et al. Differences in volatile organic compounds (VOC) determined in exhaled breath in
36	Taivans, 2013	Review, meta, letter, comment or conference abstract	Taivans I, Strazda G, Jurka N, et al. Volatile organic compounds of exhaled breath in lung cancer and lung inflammatory diseases. Eur Respir J 2
37	Hakim, 2014	Review, meta, letter, comment or conference abstract	Hakim M, Tisch U, Unger M, et al. Exhaled Volatile Organic Compounds as Noninvasive Early Molecular Markers in Lung Cancer: Bridging the G
38	Hu, 2014	Review, meta, letter, comment or conference abstract	Hu Y, Ying K. The research on early detection of lung cancer with exhaled volatile organic compounds. Eur Respir J 2014;44
39	Jareño, 2014	Review, meta, letter, comment or conference abstract	Jareño J, Munoz MA, Wagner C, et al. Volatile organic compounds (VOC) in exhaled breath in patients with lung cancer. Chest 2014;145
40	Li, 2014	Review, meta, letter, comment or conference abstract	Li W, Liu H-Y, Jia Z-R, et al. Advances in the Early Detection of Lung Cancer using Analysis of Volatile Organic Compounds: From Imaging to Se
41	Wagner, 2014	Review, meta, letter, comment or conference abstract	Wagner C, Munoz MA, Jareño J, et al. Volatile organic compounds, new biomarkers in exhaled breath samples of lung cancer patients with and
42	Westhoff, 2014	Review, meta, letter, comment or conference abstract	Westhoff M, Litterst P, Sommer HH, et al. Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation
43	Brooks, 2015	Review, meta, letter, comment or conference abstract	Brooks SW, Moore DR, Marzouk EB, et al. Canine Olfaction and Electronic Nose Detection of Volatile Organic Compounds in the Detection of C
44	Pelit, 2016	Review, meta, letter, comment or conference abstract	Pelit L, Goksel T, Dizdas TN, et al. Volatile organic compounds in exhaled breath samples as potential biomarkers in early diagnosis of lung can
45	Sun, 2016	Review, meta, letter, comment or conference abstract	Sun X, Shao K, Wang T. Detection of volatile organic compounds (VOCs) from exhaled breath as noninvasive methods for cancer diagnosis. And
46	Zhao, 2016	Review, meta, letter, comment or conference abstract	Zhao W, Al-Nasser LF, Shan S, et al. Detection of mixed volatile organic compounds and lung cancer breaths using chemiresistor arrays with creating of the second
47	Inoue, 2017	Review, meta, letter, comment or conference abstract	Inoue T, Takagi H, Owada Y, et al. Analysis of volatile organic compounds for the diagnosis of lung cancer. Cancer Res 2017;77
48	Zhou, 2017	Review, meta, letter, comment or conference abstract	Zhou J, Huang ZA, Kumar U, et al. Review of recent developments in determining volatile organic compounds in exhaled breath as biomarkers to
49	Hua, 2018	Review, meta, letter, comment or conference abstract	Hua Q, Zhu Y, Liu H. Detection of volatile organic compounds in exhaled breath to screen lung cancer: a systematic review. Future Oncol 2018;
50	Oakley-Girvan, 2018	Review, meta, letter, comment or conference abstract	Oakley-Girvan I, Davis SW. Breath based volatile organic compounds in the detection of breast, lung, and colorectal cancers: A systematic revie
51	Coyle, 2019	Review, meta, letter, comment or conference abstract	Coyle S, Chapman E, Mason S, et al. Volatile organic compounds predict the last week of life in lung cancer patients. BMJ Support Palliat Care
52	Gao, 2019	Review, meta, letter, comment or conference abstract	Gao Q, Lee WY. Urinary metabolites for urological cancer detection: a review on the application of volatile organic compounds for cancers. Am
53	Irvine, 2019	Review, meta, letter, comment or conference abstract	Irvine L, Yang I, Fong K, et al. Exhaled breath methods for analysis of volatile organic compounds (VOCS) in lung cancer and chronic obstructive
54	Marzorati, 2019	Review, meta, letter, comment or conference abstract	Marzorati D, Mainardi L, Sedda G, et al. A Metal Oxide Gas Sensors Array for Lung Cancer Diagnosis Through Exhaled Breath Analysis. Annual Society Annual International Conference 2019;2019:1584-7
55	Zhou, 2019	Review, meta, letter, comment or conference abstract	Zhou JZ. Using Volatile Organic Compounds in Exhaled Breath as a Biomarker for Early Lung Cancer Detection: A Systematic Review. 2019
56	Bohra, 2020	Review, meta, letter, comment or conference abstract	Bohra A, Kapoor N. 68P Exhaled breath analysis of volatile organic compounds (VOC) in diagnosis of lung cancer a meta-analysis. Ann Oncol 2
57	Janssens, 2020	Review, meta, letter, comment or conference abstract	Janssens E, van Meerbeeck JP, Lamote K. Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review. Crit
58	Qiu, 2020	Review, meta, letter, comment or conference abstract	Qiu M, Li H, Meng S, et al. Detection of early-stage lung cancer by exhaled volatile organic compounds using a highpressure photon ionization
59	Guo, 2021	Review, meta, letter, comment or conference abstract	Guo L, Wu H, Li Q, et al. Advances on collection and analysis of volatile organic compounds in the diagnosis of lung cancer. Chinese Journal of
60	Ratiu, 2021	Review, meta, letter, comment or conference abstract	Ratiu IA, Ligor T, Bocos-Bintintan V, et al. Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD. J
61	Gashimov, 2022	Review, meta, letter, comment or conference abstract	Gashimova EM, Temerdashev AZ, Porkhanov VA, et al. Volatile Organic Compounds in Exhaled Breath as Biomarkers of Lung Cancer: Advance
62	Listiandoko, 2022	Review, meta, letter, comment or conference abstract	Listiandoko RDW, Setyawan UA, Astuti T. EP01.01-004 The Correlation Between Exhaled Volatile Organic Compounds Using Breath Analyzer and
63	Psica, 2022	Review, meta, letter, comment or conference abstract	Psica A, Metwaly S, Sogaolu O, et al. Volatile Organic Compounds for the Detection of Hepatocellular Carcinoma - A Scoping Review. Br J Surg
64	Velusamy, 2022	Review, meta, letter, comment or conference abstract	Velusamy P, Su CH, Ramasamy P, et al. Volatile Organic Compounds as Potential Biomarkers for Noninvasive Disease Detection by Nanosenson
65	Hintzen, 2023	Review, meta, letter, comment or conference abstract	Hintzen KFH, Eussen MMM, Neutel C, et al. A systematic review on the detection of volatile organic compounds in exhaled breath in experimen
66	Krishnamoorthy, 2023	Review, meta, letter, comment or conference abstract	Krishnamoorthy A, Chandrapalan S, Bosch S, et al. The Influence of Mechanical Bowel Preparation on Volatile Organic Compounds for the Determination of Volatile Organic Compounds for the Determination of the Determinatio
67	Deng, 2004	VOCs were analyzed not in exhaled breath	Deng CH, Li N, Zhang XM. Development of headspace solid-phase microextraction with on-fiber derivatization for determination of hexanal and
68	Deng, 2004	VOCs were analyzed not in exhaled breath	Deng CH, Zhang XM, Li N. Investigation of volatile biomarkers in lung cancer blood using solid-phase microextraction and capillary gas chroma

Appendix 4 (continued)

in two populations of lung cancer (LC): With and without COPD. Eur Respir J 2013;42  $\cdot$  J 2013;42

e Gap from Bench to Bedside. Cancer Biomark Minnoninvasive Diagn Progn 2014

- Sensors. Asian Pac J Cancer Prev 2014;15:4377-84
- nd without chronic obstructive pulmonary disease. Chest 2014;145
- ation with FEV1-values. Eur Respir J 2014;44
- Cancer: A Review. Cancer Invest 2015;33:411-9
- ancer-(Ege translational pulmonology research group [EgeTPAG]). Eur Respir J 2016;48
- Anal Bioanal Chem 2016;408:2759-80
- crosslinked nanoparticle thin films. Sensor Actuat B-Chem 2016;232:292-9
- ers for lung cancer diagnosis. Anal Chim Acta 2017;996:1-9
- 18;14:1647-62
- eview. Cancer Biomarkers 2018;21:29-39
- are 2019;9:A27
- Am J Clin Exp Urol 2019;7:232-48
- tive pulmonary disease (COPD). Respirology 2019;24:84
- ual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology

crit Rev Oncol Hematol 2020;153 ion timeof-flight mass spectrometry. J Clin Oncol 2020;38 al of Lung Cancer 2021;24:796-803 D. J Clin Med 2021;10 inces and Potential Problems. J Anal Chem 2022;77:785-810 er and Interleukin-23 (IL-23) in Lung Cancer. J Thorac Oncol 2022;17:S161 Surg 2022;109:ix37 insors: A Comprehensive Review. Crit Rev Anal Chem 2022:1-12 mental animals in the context of gastrointestinal and hepatic diseases. PLoS One 2023;18:e0291636 Detection of Gastrointestinal Disease-A Systematic Review. Sensors (Basel) 2023;23 and heptanal in human blood. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:47-52 comatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004;808:269-77

Appendix 4	(continued)
------------	-------------

Appen	<b>dix 4</b> (continued)		
No.	Study, year	Main reason	Citations
69	Chen, 2007	VOCs were analyzed not in exhaled breath	Chen X, Xu F, Wang Y, et al. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. CANCER 2007
70	Filipiak, 2008	VOCs were analyzed not in exhaled breath	Filipiak W, Sponring A, Mikoviny T, et al. Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer C
71	Руо, 2008	VOCs were analyzed not in exhaled breath	Pyo JS, Ju HK, Park JH, et al. Determination of volatile biomarkers for apoptosis and necrosis by solid-phase microextraction-gas chromatogra Chromatogr B Analyt Technol Biomed Life Sci 2008;876:170-4
72	Barash, 2009	VOCs were analyzed not in exhaled breath	Barash O, Peled N, Hirsch FR, et al. Sniffing the Unique "Odor Print" of Non-Small-Cell Lung Cancer with Gold Nanoparticles. SMALL 2009;5:2
73	Sponring, 2009	VOCs were analyzed not in exhaled breath	Sponring A, Filipiak W, Mikoviny T, et al. Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Re
74	Barta, 2010	VOCs were analyzed not in exhaled breath	Barta I, Kullmann T, Csiszer E, et al. Analysis of cytokine pattern in exhaled breath condensate of patients with squamous cell lung carcinoma. I
75	Filipiak, 2010	VOCs were analyzed not in exhaled breath	Filipiak W, Sponring A, Filipiak A, et al. TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. Cancer Epide
76	Sponring, 2010	VOCs were analyzed not in exhaled breath	Sponring A, Filipiak W, Ager C, et al. Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. Cancer E
77	Guadagni, 2011	VOCs were analyzed not in exhaled breath	Guadagni R, Miraglia N, Simonelli A, et al. Solid-phase microextraction-gas chromatography-mass spectrometry method validation for the dete
78	Barash, 2012	VOCs were analyzed not in exhaled breath	Barash O, Peled N, Tisch U, et al. Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine: NBM 2012;8:580-9.
79	Hanai, 2012	VOCs were analyzed not in exhaled breath	Hanai Y, Shimono K, Matsumura K, et al. Urinary Volatile Compounds as Biomarkers for Lung Cancer. Biosci Biotechnol Biochem 2012;76:679-
80	Hanai, 2012	VOCs were analyzed not in exhaled breath	Hanai Y, Shimono K, Oka H, et al. Analysis of volatile organic compounds released from human lung cancer cells and from the urine of tumor-be
81	Rutter, 2013	VOCs were analyzed not in exhaled breath	Rutter AV, Chippendale TWE, Yang Y, et al. Quantification by SIFT-MS of acetaldehyde released by lung cells in a 3D model. Analyst 2013;138:9
82	Davies, 2014	VOCs were analyzed not in exhaled breath	Davies MPA, Barash O, Jeries R, et al. Unique volatolomic signatures of TP53 and KRAS in lung cells. Br J Cancer 2014;111:1213-21.
83	Hubers, 2014	VOCs were analyzed not in exhaled breath	Hubers AJ, Brinkman P, Boksem RJ, et al. Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis. J Clin Pathol 201
84	Liu, 2014	VOCs were analyzed not in exhaled breath	Liu H, Li C, Wang H, et al. Characterization of Volatile Organic Metabolites in Lung Cancer Pleural Effusions by SPME-GC/MS Combined with a
85	Liu, 2014	VOCs were analyzed not in exhaled breath	Liu H, Wang H, Li C, et al. Investigation of volatile organic metabolites in lung cancer pleural effusions by solid-phase microextraction and gas of
86	Rozhentsov, 2014	VOCs were analyzed not in exhaled breath	Rozhentsov AA, Koptina AV, Mitrakov AA, et al. A new method to diagnose cancer based on image analysis of mass chromatograms of volatile
87	Villeneuve, 2014	VOCs were analyzed not in exhaled breath	Villeneuve PJ, Jerrett M, Brenner D, et al. A Case-Control Study of Long-Term Exposure to Ambient Volatile Organic Compounds and Lung Can
88	Yuan, 2014	VOCs were analyzed not in exhaled breath	Yuan JM, Butler LM, Gao YT, et al. Urinary metabolites of a polycyclic aromatic hydrocarbon and volatile organic compounds in relation to lung
89	Corradi, 2015	VOCs were analyzed not in exhaled breath	Corradi M, Poli D, Banda I, et al. Exhaled breath analysis in suspected cases of non-small-cell lung cancer: a cross-sectional study. J Breath Re
90	Mazzone, 2015	VOCs were analyzed not in exhaled breath	Mazzone PJ, Wang XF, Lim S, et al. Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer. BMC Cancer 20
91	Schallschmidt, 2015	VOCs were analyzed not in exhaled breath	Schallschmidt K, Becker R, Zwaka H, et al. In vitro cultured lung cancer cells are not suitable for animal-based breath biomarker detection. J Br
92	Peralbo-Molina, 2016	VOCs were analyzed not in exhaled breath	Peralbo-Molina A, Calderon-Santiago M, Priego-Capote F, et al. Identification of metabolomics panels for potential lung cancer screening by an
93	Peralbo-Molina, 2016	VOCs were analyzed not in exhaled breath	Peralbo-Molina A, Calderon-Santiago M, Priego-Capote F, et al. Metabolomics analysis of exhaled breath condensate for discrimination betwee
94	Pérez, 2016	VOCs were analyzed not in exhaled breath	Pérez Antón A, Ramos Á, Del Nogal Sánchez M, et al. Headspace-programmed temperature vaporization-mass spectrometry for the rapid dete
95	Schmidt, 2016	VOCs were analyzed not in exhaled breath	Schmidt KZ. In Vitro Analysis of Volatile Organic Compounds in Search of Potential Biomarkers of Lung Cancer. 2016.
96	Bianchi, 2017	VOCs were analyzed not in exhaled breath	Bianchi F, Riboni N, Carbognani P, et al. Solid-phase microextraction coupled to gas chromatography-mass spectrometry followed by multivaria Biomed Anal 2017;146:329-33.
97	Feinberg, 2017	VOCs were analyzed not in exhaled breath	Feinberg T, Herbig J, Kohl I, et al. Cancer metabolism: the volatile signature of glycolysis-in vitro model in lung cancer cells. J Breath Res 2017;
98	Garcia, 2017	VOCs were analyzed not in exhaled breath	Garcia Ramos A, Perez Anton A, del Nogal Sanchez M, et al. Urinary volatile fingerprint based on mass spectrometry for the discrimination of p
99	Santos, 2017	VOCs were analyzed not in exhaled breath	Santos PM, Del Nogal Sánchez M, Pozas ÁC, et al. Determination of ketones and ethyl acetate-a preliminary study for the discrimination of pati
100	Jia, 2018	VOCs were analyzed not in exhaled breath	Jia Z, Zhang H, Ong CN, et al. Detection of Lung Cancer: Concomitant Volatile Organic Compounds and Metabolomic Profiling of Six Cancer C
101	Porto-Figueira, 2018	VOCs were analyzed not in exhaled breath	Porto-Figueira P, Pereira J, Miekisch W, et al. Exploring the potential of NTME/GC-MS, in the establishment of urinary volatomic profiles. Lung of

Appendix 4 (continued)

### 007;110:835-44

#### r Cell Int 2008;8

graphy/mass spectrometry: A pharmacometabolomic approach to cisplatin's cytotoxicity to human lung cancer cell lines. J

- 5:2618-24
- Res 2009;29:419-26
- a. Int J Biol Markers 2010;25:52-6.
- idemiol Biomarkers Prev 2010;19:182-95.
- er Biomarkers 2010;7:153-61.
- etermination of endogenous substances: Urinary hexanal and heptanal as lung tumor biomarkers. Anal Chim Acta 2011;701:29-36.

#### 79-84.

- r-bearing mice. Cancer Cell Int 2012;12.
- 8:91-5.

### 2014;67:707-11.

- n an Untargeted Metabolomic Method. Chromatographia 2014;77:1379-86.
- as chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2014;945:53-9.
- tile organic compounds in urine. Sovrem Tehnol Med 2014;6:151-7.
- Cancer in Toronto, Ontario, Canada. Am J Epidemiol 2014;179:443-51.
- ng cancer development in lifelong never smokers in the Shanghai Cohort Study. Carcinogenesis 2014;35:339-45.
- Res 2015;9.
- 2015;15.
- J Breath Res 2015;9:027103.
- analysis of exhaled breath condensate. J Breath Res 2016;10.
- ween lung cancer patients and risk factor individuals. J Breath Res 2016;10.
- etermination of possible volatile biomarkers of lung cancer in urine. Anal Bioanal Chem 2016;408:5239-46.

ariate data analysis for the identification of volatile organic compounds as possible biomarkers in lung cancer tissues. J Pharm

#### 17;11:016008.

- f patients with lung cancer and controls. Talanta 2017;174:158-64.
- patients with lung cancer. Anal Bioanal Chem 2017;409:5689-96.
- r Cell Lines of Different Histological Origins. ACS Omega 2018;3:5131-40.
- g cancer patients as case study. Sci Rep 2018;8.

Append	lix 4	(continued)
--------	-------	-------------

	(continueu)		
No.	Study, year	Main reason	Citations
102	Thriumani, 2018	VOCs were analyzed not in exhaled breath	Thriumani R, Zakaria A, Hashim YZH-Y, et al. A study on volatile organic compounds emitted by in-vitro lung cancer cultured cells using gas se
103	Mohamed, 2019	VOCs were analyzed not in exhaled breath	Mohamed EI, Mohamed MA, Abdel-Mageed SM, et al. Volatile organic compounds of biofluids for detecting lung cancer by an electronic nose
104	Sun, 2019	VOCs were analyzed not in exhaled breath	Sun Y, Chen Y, Sun C, et al. Analysis of volatile organic compounds from patients and cell lines for the validation of lung cancer biomarkers by
105	Chu, 2020	VOCs were analyzed not in exhaled breath	Chu Y, Zhou J, Ge D, et al. Variable VOCs in plastic culture flasks and their potential impact on cell volatile biomarkers. Anal Bioanal Chem 202
106	Chen, 2021	VOCs were analyzed not in exhaled breath	Chen K-C, Tsai S-W, Zhang X, et al. The investigation of the volatile metabolites of lung cancer from the microenvironment of malignant pleural
107	Cho, 2021	VOCs were analyzed not in exhaled breath	Cho SW, Ko HJ, Park TH. Identification of a Lung Cancer Biomarker Using a Cancer Cell Line and Screening of Olfactory Receptors for Bioma
108	Einoch-Amor, 2021	VOCs were analyzed not in exhaled breath	Einoch-Amor R, Broza YY, Haick H. Detection of Single Cancer Cells in Blood with Artificially Intelligent Nanoarray. ACS Nano 2021;15:7744-55
109	Choueiry, 2022	VOCs were analyzed not in exhaled breath	Choueiry F, Zhu J. Secondary electrospray ionization-high resolution mass spectrometry (SESI-HRMS) fingerprinting enabled treatment monito
110	Gasparri, 2022	VOCs were analyzed not in exhaled breath	Gasparri R, Capuano R, Guaglio A, et al. Volatolomic urinary profile analysis for diagnosis of the early stage of lung cancer. J Breath Res 2022;
111	Janssens, 2022	VOCs were analyzed not in exhaled breath	Janssens E, Mol Z, Vandermeersch L, et al. Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lir
112	Jongkhumkrong, 2022	VOCs were analyzed not in exhaled breath	Jongkhumkrong J, Thaveesangsakulthai I, Sukbangnop W, et al. Helicene-Hydrazide Encapsulated Ethyl Cellulose as a Potential Fluorescence Appl Mater Interfaces 2022.
113	Chapman, 2023	VOCs were analyzed not in exhaled breath	Chapman EA, Baker J, Aggarwal P, et al. GC-MS Techniques Investigating Potential Biomarkers of Dying in the Last Weeks with Lung Cancer.
114	Einoch, 2023	VOCs were analyzed not in exhaled breath	Einoch Amor R, Levy J, Broza YY, et al. Liquid Biopsy-Based Volatile Organic Compounds from Blood and Urine and Their Combined Data Set
115	Liu, 2023	VOCs were analyzed not in exhaled breath	Liu S-F, Lu H-I, Chi W-L, et al. Sniffer Dogs Diagnose Lung Cancer by Recognition of Exhaled Gases: Using Breathing Target Samples to Train
116	Sani, 2023	VOCs were analyzed not in exhaled breath	Sani SN, Zhou W, Ismail BB, et al. LC-MS/MS Based Volatile Organic Compound Biomarkers Analysis for Early Detection of Lung Cancer. CAN
117	Wiesel, 2023	VOCs were analyzed not in exhaled breath	Wiesel O, Sung SW, Katz A, et al. A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection. Biosensors 2023;13.
118	Phillips, 2003	No complete collection methods	Phillips M, Cataneo RN, Cummin ARC, et al. Detection of lung cancer with volatile markers in the breath. Chest 2003;123:2115-23.
119	Machado, 2005	No complete collection methods	Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care M
120	Castro, 2011	No complete collection methods	Castro M, Kumar B, Feller JF, et al. Novel e-nose for the discrimination of volatile organic biomarkers with an array of carbon nanotubes (CNT)
121	Darwiche, 2011	No complete collection methods	Darwiche K, Baumbach JI, Sommerwerck U, et al. Bronchoscopically Obtained Volatile Biomarkers in Lung Cancer. Lung 2011;189:445-52.
122	Liu, 2011	No complete collection methods	Liu FL, Xiao P, Fang HL, et al. Single-walled carbon nanotube-based biosensors for the detection of volatile organic compounds of lung cancer
123	Ehmann, 2012	No complete collection methods	Ehmann R, Boedeker E, Friedrich U, et al. Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon. Eur Respi
124	Chatterjee, 2013	No complete collection methods	Chatterjee S, Castro M, Feller JF. An e-nose made of carbon nanotube based quantum resistive sensors for the detection of eighteen polar/nor
125	Hou, 2013	No complete collection methods	Hou C, Lei J, Huo D, et al. Discrimination of Lung Cancer Related Volatile Organic Compounds with a Colorimetric Sensor Array. Anal Lett 2013
126	Handa, 2014	No complete collection methods	Handa H, Usuba A, Maddula S, et al. Exhaled Breath Analysis for Lung Cancer Detection Using Ion Mobility Spectrometry. PLoS One 2014;9.
127	Wang, 2014	No complete collection methods	Wang C, Dong R, Wang X, et al. Exhaled volatile organic compounds as lung cancer biomarkers during one-lung ventilation. Sci Rep 2014;4.
128	Wu, 2014	No complete collection methods	Wu Y, Huo D, Hou C, et al. Colorimetric Artificial Nose for Identification of Breath Volatile Organic Compounds of Patients with Lung Cancer. Ch
129	de Vries R, 2015	No complete collection methods	de Vries R, Brinkman P, van der Schee MP, et al. Integration of electronic nose technology with spirometry: validation of a new approach for ex
130	Lei, 2015	No complete collection methods	Lei J-c, Hou C-j, Huo D-q, et al. A novel device based on a fluorescent cross-responsive sensor array for detecting lung cancer related volatile
131	Mazzone, 2015	No complete collection methods	Mazzone PJ, Wang XF, Lim S, et al. Progress in the development of volatile exhaled breath signatures of lung cancer. Ann Am Thorac Soc 2015
132	Zhang, 2016	No complete collection methods	Zhang X-F, Zhang Z-W, He Y-L, et al. Sniffing lung cancer related biomarkers using an oxidized graphene SAW sensor. Front Phys 2016;11.
133	Chen, 2017	No complete collection methods	Chen X, Wang F, Lin L, et al. Association of Smoking with Metabolic Volatile Organic Compounds in Exhaled Breath. Int J Mol Sci 2017;18.
134	Kort, 2017	No complete collection methods	Kort S, Brusse-Keizer M, Gerritsen J-W, et al. Data analysis of electronic nose technology in lung cancer: generating prediction models by mea
135	Li, 2017	No complete collection methods	Li Z, Xu C, Shu J, et al. Doping-assisted low-pressure photoionization mass spectrometry for the real-time detection of lung cancer-related vol-

Appendix 4 (continued)

sensor array and SPME-GCMS. BMC Cancer 2018;18.

se based on artificial neural network. J Appl Biomed 2019;17:61-7.

by proton-transfer-reaction mass spectrometry. Anal Methods 2019;11:3188-97.

2020;412:5397-408.

ral effusion. Sci Rep 2021;11.

narker Detection. Biotechnol Bioprocess Eng 2021;26:55-62.

-55.

itoring of pulmonary carcinoma cells in real time. Anal Chim Acta 2022;1189.

22;16.

Lines as Translational Bridge for Breath Research. Front Oncol 2022;12.

nce Sensor for Highly Specific Detection of Nonanal in Aqueous Solutions and a Proof-of-Concept Clinical Study in Lung Fluid. ACS

er. Int J Mol Sci 2023;24.

Sets for Highly Accurate Detection of Cancer. ACS Sens 2023;8:1450-61.

in Dogs Has a Higher Diagnostic Rate Than Using Lung Cancer Tissue Samples or Urine Samples. CANCERS 2023;15. ANCERS 2023;15.

Med 2005;171:1286-91.

IT) conductive polymer nanocomposites (CPC) sensors. Sensor Actuat B-Chem 2011;159:213-9.

cer. Physica E 2011;44:367-72.

spir J 2012;39:669-76.

nonpolar VOC biomarkers of lung cancer. J Mater Chem B 2013;1:4563-75.

013;46:2048-59.

Chem Res Chin Univ 2014;30:572-7.

exhaled breath analysis. J Breath Res 2015;9.

ile organic compounds. Rev Sci Instrum 2015;86.

015;12:752-7.

neans of Aethena. J Breath Res 2017;11.

volatile organic compounds. Talanta 2017;165:98-106.

Ap	pendix	4	(continued)

	Аррепо	lix 4 (continuea)		
_	No.	Study, year	Main reason	Citations
-	136	Liu, 2017	No complete collection methods	Liu L, Zhang D, Zhang Q, et al. Smartphone-based sensing system using ZnO and graphene modified electrodes for VOCs detection. Biosens B
	137	Nag, 2017	No complete collection methods	Nag S, Castro M, Choudhary V, et al. Sulfonated poly(ether ether ketone) [SPEEK] nanocomposites based on hybrid nanocarbons for the detection
	138	Oguma, 2017	No complete collection methods	Oguma T, Nagaoka T, Kurahashi M, et al. Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer. PLoS One
	139	Saalberg, 2017	No complete collection methods	Saalberg Y, Bruhns H, Wolff M. Photoacoustic Spectroscopy for the Determination of Lung Cancer Biomarkers-A Preliminary Investigation. Sens
	140	Zhang, 2017	No complete collection methods	Zhang Z, Yu W, Wang J, et al. Ultrasensitive Surface-Enhanced Raman Scattering Sensor of Gaseous Aldehydes as Biomarkers of Lung Cancer
	141	Gregis, 2018	No complete collection methods	Gregis G, Sanchez J-B, Bezyerkhyy I, et al. Detection and quantification of lung cancer biomarkers by a micro-analytical device using a single m
	142	Kort, 2018	No complete collection methods	Kort S, Tiggeloven MM, Brusse-Keizer M, et al. Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysi
	143	Nagarajan, 2018	No complete collection methods	Nagarajan V, Chandiramouli R. Novel method to detect the lung cancer biomarker volatiles using hydrogen vacant silicane nanosheets: A DFT in
	144	Qiao, 2018	No complete collection methods	Qiao X, Su B, Liu C, et al. Selective Surface Enhanced Raman Scattering for Quantitative Detection of Lung Cancer Biomarkers in Superparticle
	145	Rocco, 2018	No complete collection methods	Rocco G. Every breath you take: The value of the electronic nose (e-nose) technology in the early detection of lung cancer. J Thorac Cardiovasc
	146	Wan, 2018	No complete collection methods	Wan Q, Xu Y, Xiao H. Exhaled gas detection by Ir-doped CNT for primary diagnosis of lung cancer. AIP Adv 2018;8.
	147	Zhao, 2018	No complete collection methods	Zhao G, Li M. Ni-doped MoS <sub>2</sub> biosensor: a promising candidate for early diagnosis of lung cancer by exhaled breathe analysis. Ap
	148	Zhao, 2018	No complete collection methods	Zhao S, Lei J, Huo D, et al. A colorimetric detector for lung cancer related volatile organic compounds based on cross-response mechanism. Se
	149	van de Goor R, 2018	No complete collection methods	van de Goor R, van Hooren M, Dingemans A-M, et al. Training and Validating a Portable Electronic Nose for Lung Cancer Screening. J Thorac O
	150	Zhong, 2018	No complete collection methods	Zhong X, Li D, Du W, et al. Rapid recognition of volatile organic compounds with colorimetric sensor arrays for lung cancer screening. Anal Bioar
	151	Kovalska, 2019	No complete collection methods	Kovalska E, Lesongeur P, Hogan BT, et al. Multi-layer graphene as a selective detector for future lung cancer biosensing platforms. Nanoscale 20
	152	Lu, 2019	No complete collection methods	Lu B, Fu L, Nie B, et al. A Novel Framework with High Diagnostic Sensitivity for Lung Cancer Detection by Electronic Nose. Sensors 2019;19.
	153	Tirzite, 2019	No complete collection methods	Tirzite M, Bukovskis M, Strazda G, et al. Detection of lung cancer with electronic nose and logistic regression analysis. J Breath Res 2019;13.
	154	Kononov, 2020	No complete collection methods	Kononov A, Korotetsky B, Jahatspanian I, et al. Online breath analysis using metal oxide semiconductor sensors (electronic nose) for diagnosis of
	155	Kort, 2020	No complete collection methods	Kort S, Brusse-Keizer M, Gerritsen JW, et al. Improving lung cancer diagnosis by combining exhaled-breath data and clinical parameters. ERJ O
	156	Majidi, 2020	No complete collection methods	Majidi R, Nadafan M. Detection of exhaled gas by $\gamma$ -graphyne and twin-graphene for early diagnosis of lung cancer: A density functional theory s
	157	Xu, 2020	No complete collection methods	40. Xu Y, Jiang J, Bu H, et al. A dual-channel self-calibrating multi-parameter sensor for lung cancer-related exhaled marker rapid identification.
	158	Zhang, 2020	No complete collection methods	Zhang X, Zhang Q, Wang X, et al. Structured sparse logistic regression with application to lung cancer prediction using breath volatile biomarker
	159	Mirzaei, 2021	No complete collection methods	Mirzaei M, Gulseren O, Rafienia M, et al. Nanocarbon-assisted biosensor for diagnosis of exhaled biomarkers of lung cancer: DFT approach. Eu
	160	Wan, 2022	No complete collection methods	Wan Q, Chen X, Xiao S. Ru-Doped PtTe <sub>2</sub> Monolayer as a Promising Exhaled Breath Sensor for Early Diagnosis of Lung Cancer: A F
	161	Zhang, 2022	No complete collection methods	Zhang Z-J, Li P-W, Liu L-P, et al. Amine-functionalized UiO-66 as a fluorescent sensor for highly selective detecting volatile organic compound b
	162	Zou, 2022	No complete collection methods	Zou Y, Hu Y, Jiang Z, et al. Exhaled metabolic markers and relevant dysregulated pathways of lung cancer: a pilot study. Ann Med 2022;54:790-8
	163	Li, 2023	No complete collection methods	Li L, Tian Z-W, Zhao W-H, et al. "Sniff"lung cancer biomarkers in breath using N-doped monolayer WS2: A theoretical feasibility. Appl Surf Sci 20
	164	Liu, 2023	No complete collection methods	Liu L, Ru L, Tang H, et al. A multi-responsive Tb-doped MOF probe for highly specific breath volatile biomarker recognition of lung cancer. J Mat
	165	Mashhadbani, 2023	No complete collection methods	Mashhadbani M, Faizabadi E. Early detection of lung cancer biomarkers in exhaled breath by modified armchair stanene nanoribbons. PCCP 20
	166	Guirao, 2017	Use trained dogs to analysis VOCs	Guirao Montes A, Molins Lopez-Rodo L, Ramon Rodriguez I, et al. Lung cancer diagnosis by trained dogs. Eur J Cardiothorac Surg 2017;52:120
	167	Fischer-Tenhagen, 2018	Use trained dogs to analysis VOCs	Fischer-Tenhagen C, Johnen D, Nehls I, et al. A Proof of Concept: Are Detection Dogs a Useful Tool to Verify Potential Biomarkers for Lung Cancel
	168	Guirao, 2019	Use trained dogs to analysis VOCs	Guirao A, Molins L, Ramon I, et al. Trained dogs can identify malignant solitary pulmonary nodules in exhaled gas. Lung Cancer 2019;135:230-3.
	169	Mazzola, 2020	Use trained dogs to analysis VOCs	Mazzola SM, Pirrone F, Sedda G, et al. Two-step investigation of lung cancer detection by sniffer dogs. J Breath Res 2020;14.
	170	Feil, 2021	Use trained dogs to analysis VOCs	Feil C, Staib F, Berger MR, et al. Sniffer dogs can identify lung cancer patients from breath and urine samples. BMC Cancer 2021;21.
	171	Crawford, 2022	Use trained dogs to analysis VOCs	Crawford MA, Perrone JA, Browne CM, et al. Transitioning from training to testing with scent detection animals: Application to lung cancer detection
_				

s Bioelectron 2017;93:94-101.

ection and discrimination of some lung cancer VOC biomarkers. J Mater Chem B 2017;5:348-59.

One 2017;12.

ensors 2017;17.

cer on Dendritic Ag Nanocrystals. Anal Chem 2017;89:1416-20.

e metal oxide-based gas sensor. Sensor Actuat B-Chem 2018;255:391-400.

lysis. Lung Cancer 2018;125:223-9.

Finvestigation. Comput Theor Chem 2018;1138:107-16.

cle@MOF Structure. Adv Mater 2018;30.

Isc Surg 2018;155:2622-5.

Appl Phys A-Mater 2018;124.

Sensor Actuat B-Chem 2018;256:543-52.

Oncol 2018 13:676-81.

oanal Chem 2018 410:3671-81.

e 2019;11:2476-83.

is of lung cancer. J Breath Res 2020;14.

J OPEN RESEARCH 2020;6.

ry study. Phys Lett A 2020;384.

n. Anal Methods 2020;12:620-9.

kers. Stat Med 2020;39:955-67.

Eurasian Chemical Communications 2021;3:154-61.

A First-Principles Study. Chemosensors 2022;10.

d biomarker of lung cancer. J Solid State Chem 2022;305.

0-802.

i 2023;614.

Mater Chem C 2023;11:3059-69.

2023;25:3875-89.

1206-10.

ancer? Front Vet Sci 2018;5.

)-3.

Appendix 5	89	articles	included	in	full text	
------------	----	----------	----------	----	-----------	--

LL .		
No.	Study, year	Citations
1	Phillips, 1999	Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999;353:1930-3.
2	Yu, 2005	Yu H, Xu L, Wang P. Solid phase microextraction for analysis of alkanes and aromatic hydrocarbons in human breath. J Chromatogr B Analyt Technol Biomed Life Sci 2005;826:69-74.
3	Phillips, 2007	Phillips M, Altorki N, Austin JHM, et al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomarkers 2007;3:95-109.
4	Wehinger, 2007	Wehinger A, Schmid A, Mechtcheriakov S, et al. Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas. Int J Mass Spectrom 2007;265:49-59.
5	Phillips, 2008	Phillips M, Altorki N, Austin JHM, et al. Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta 2008;393:76-84.
6	Bajtarevic, 2009	Bajtarevic A, Ager C, Pienz M, et al. Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 2009;9.
7	Gaspar, 2009	Gaspar EM, Lucena AF, Duro da Costa J, et al. Organic metabolites in exhaled human breatha multivariate approach for identification of biomarkers in lung disorders. J chromatogr A 2009;1216:2749-56
8	Ligor, 2009	Ligor M, Ligor T, Bajtarevic A, et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrome
9	Peng, 2009	Peng G, Tisch U, Adams O, et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol 2009;4:669-73.
10	Westhoff, 2009	Westhoff M, Litterst P, Freitag L, et al. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax 2009;64:744-
11	Fuchs, 2010	Fuchs P, Loeseken C, Schubert JK, et al. Breath gas aldehydes as biomarkers of lung cancer. Int J Cancer 2010;126:2663-70.
12	Poli, 2010	Poli D, Goldoni M, Corradi M, et al. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. J Chromatogr B Analyt Technol Biomed Li
13	Kischkel, 2010	Kischkel S, Miekisch W, Sawacki A, et al. Breath biomarkers for lung cancer detection and assessment of smoking related effects - confounding variables, influence of normalization and statistical algorith
14	Song, 2010	Song G, Qin T, Liu H, et al. Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 2010;67:227-31.
15	Tran, 2010	Tran VH, Chan HP, Thurston M, et al. Breath Analysis of Lung Cancer Patients Using an Electronic Nose Detection System. IEEE Sens J 2010;10:1514-8.
16	Buszewski, 2011	Buszewski B, Ulanowska A, Kowalkowski T, et al. Investigation of lung cancer biomarkers by hyphenated separation techniques and chemometrics. Clin Chem Lab Med 2011;50:573-81.
17	Rudnicka, 2011	Rudnicka J, Kowalkowski T, Ligor T, et al. Determination of volatile organic compounds as biomarkers of lung cancer by SPME-GC-TOF/MS and chemometrics. J Chromatogr B Analyt Technol Biomed Lif
18	Ulanowska, 2011	Ulanowska A, Kowalkowski T, Trawinska E, et al. The application of statistical methods using VOCs to identify patients with lung cancer. J Breath Res 2011;5.
19	Buszewski, 2012	Buszewski B, Ligor T, Jezierski T, et al. Identification of volatile lung cancer markers by gas chromatography-mass spectrometry: comparison with discrimination by canines. Anal Bioanal Chem 2012;404:
20	Filipiak, 2014	Filipiak W, Filipiak A, Sponring A, et al. Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath marker
21	Gi, 2014	Gi BH, Jeung S, Ok LJ, et al. Exhaled Breath Analysis System based on Electronic Nose Techniques Applicable to Lung Diseases. Hanyang Med Rev 2014;34:125-9.
22	Ma, 2014	Ma H, Li X, Chen J, et al. Analysis of human breath samples of lung cancer patients and healthy controls with solid-phase microextraction (SPME) and flow-modulated comprehensive two-dimensional gas 2014;6:6841-9.
23	Phillips, 2015	Phillips M, Bauer TL, Cataneo RN, et al. Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening. PLoS One 2015;10.
24	Ligor, 2015	Ligor T, Pater L, Buszewski B. Application of an artificial neural network model for selection of potential lung cancer biomarkers. J Breath Res 2015;9.
25	Gasparri, 2016	Gasparri R, Santonico M, Valentini C, et al. Volatile signature for the early diagnosis of lung cancer. J Breath Res 2016;10:016007.
26	ltoh, 2016	Itoh T, Miwa T, Tsuruta A, et al. Development of an Exhaled Breath Monitoring System with Semiconductive Gas Sensors, a Gas Condenser Unit, and Gas Chromatograph Columns. Sensors (Basel) 2016;
27	Sakumura, 2017	Sakumura Y, Koyama Y, Tokutake H, et al. Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector Machine Algorithm. Sensors (Basel) 2017;17.
28	Cai, 2017	Cai X, Chen L, Kang T, et al. A Prediction Model with a Combination of Variables for Diagnosis of Lung Cancer. Med Sci Monit 2017;23:5620-9.
29	Chang, 2018	Chang J-E, Lee D-S, Ban S-W, et al. Analysis of volatile organic compounds in exhaled breath for lung cancer diagnosis using a sensor system. Sensor Actuat B-Chem 2018;255:800-7.
30	Huang, 2018	Huang C-H, Zeng C, Wang Y-C, et al. A Study of Diagnostic Accuracy Using a Chemical Sensor Array and a Machine Learning Technique to Detect Lung Cancer. Sensors (Basel) 2018;18.
31	Yu, 2018	Yu L-Q, Wang L-Y, Su F-H, et al. A gate-opening controlled metal-organic framework for selective solid-phase microextraction of aldehydes from exhaled breath of lung cancer patients. Microchim Acta 20
32	Li, 2019	Li W, Dai W, Liu M, et al. VOC biomarkers identification and predictive model construction for lung cancer based on exhaled breath analysis: research protocol for an exploratory study. BMJ Open Sci 2019
33	Pesesse, 2019	Pesesse R, Stefanuto PH, Schleich F, et al. Multimodal chemometric approach for the analysis of human exhaled breath in lung cancer patients by TD-GC×GC-TOFMS. J Chromatogr B Analyt Technol Bio
34	Rudnicka, 2019	Rudnicka J, Kowalkowski T, Buszewski B. Searching for selected VOCs in human breath samples as potential markers of lung cancer. Lung Cancer 2019;135:123-9.

Appendix 5 (continued)

-56. ometry. Clin Chem Lab Med 2009;47:550-60.

14-8.

d Life Sci 2010;878:2643-51. rithms. Clin Chim Acta 2010;411:1637-44.

Life Sci 2011;879:3360-6.

04:141-6. kers. J Breath Res 2014;8.

gas chromatography (GC x GC). Anal Methods

6;16.

a 2018;185. 019;9. Biomed Life Sci 2019;1114-1115:146-53. Appendix 5 (continued)

No.	Study, year	Citations
35	Chen, 2020	Chen Q, Chen Z, Liu D, et al. Constructing an E-Nose Using Metal-Ion-Induced Assembly of Graphene Oxide for Diagnosis of Lung Cancer via Exhaled Breath. ACS Appl Mater Interfaces 2020;12:17725-3
36	Gashimova, 2020	Gashimova E, Temerdashev A, Porkhanov V, et al. Investigation of different approaches for exhaled breath and tumor tissue analyses to identify lung cancer biomarkers. Heliyon 2020;6.
37	Koureas, 2020	Koureas M, Kirgou P, Amoutzias G, et al. Target Analysis of Volatile Organic Compounds in Exhaled Breath for Lung Cancer Discrimination from Other Pulmonary Diseases and Healthy Persons. Metabolite
38	Li, 2020	Li W, Jia Z, Xie D, et al. Recognizing lung cancer using a homemade e-nose: A comprehensive study. Comput Biol Med 2020;120.
39	Saidi, 2020	Saidi T, Moufid M, de Jesus Beleno-Saenz K, et al. Non-invasive prediction of lung cancer histological types through exhaled breath analysis by UV-irradiated electronic nose and GC/QTOF/MS. Sensor Ac
40	Chen, 2021	Chen K, Liu L, Nie B, et al. Recognizing lung cancer and stages using a self-developed electronic nose system. Comput Biol Med 2021;131.
41	Gashimova, 2021	Gashimova E, Osipova A, Temerdashev A, et al. Study of confounding factors influence on lung cancer diagnostics effectiveness using gas chromatography-mass spectrometry analysis of exhaled breath.
42	Koureas, 2021	Koureas M, Kalompatsios D, Amoutzias GD, et al. Comparison of Targeted and Untargeted Approaches in Breath Analysis for the Discrimination of Lung Cancer from Benign Pulmonary Diseases and Heal 2021;26.
43	Lee, 2021	Lee JM, Choi EJ, Chung JH, et al. A DNA-derived phage nose using machine learning and artificial neural processing for diagnosing lung cancer. Biosens Bioelectron 2021;194.
44	Li, 2021	Li Z, Li Y, Zhan L, et al. Point-of-Care Test Paper for Exhaled Breath Aldehyde Analysis via Mass Spectrometry. Anal Chem 2021;93:9158-65.
45	Liu, 2021	Liu B, Yu H, Zeng X, et al. Lung cancer detection via breath by electronic nose enhanced with a sparse group feature selection approach. Sensor Actuat B-Chem 2021;339.
46	Liu, 2021	Liu B, Zeng X, Yu H, et al. Sparse Unidirectional Domain Adaptation Algorithm for Instrumental Variation Correction of Electronic Nose Applied to Lung Cancer Detection. IEEE Sens J 2021;21:17025-39.
47	Long, 2021	Long Y, Wang C, Wang T, et al. High performance exhaled breath biomarkers for diagnosis of lung cancer and potential biomarkers for classification of lung cancer. J Breath Res 2021;15.
48	Xia, 2021	Xia Z, Li D, Deng W. Identification and Detection of Volatile Aldehydes as Lung Cancer Biomarkers by Vapor Generation Combined with Paper-Based Thin-Film Microextraction. Anal Chem 2021;93:4924-3
49	Zou, 2021	Zou Y, Wang Y, Jiang Z, et al. Breath profile as composite biomarkers for lung cancer diagnosis. Lung Cancer 2021;154:206-13.
50	Tsou, 2021	Tsou P-H, Lin Z-L, Pan Y-C, et al. Exploring Volatile Organic Compounds in Breath for High-Accuracy Prediction of Lung Cancer. Cancers (Basel) 2021;13.
51	Gashimova, 2022	Gashimova E, Temerdashev A, Porkhanov V, et al. Non-invasive Exhaled Breath and Skin Analysis to Diagnose Lung Cancer: Study of Age Effect on Diagnostic Accuracy. ACS Omega 2022;7:42613-28.
52	Larracy, 2022	Larracy R, Phinyomark A, Scheme E. Infrared cavity ring-down spectroscopy for detecting non-small cell lung cancer in exhaled breath. J Breath Res 2022;16.
53	Wang, 2022	Wang P, Huang Q, Meng S, et al. Identification of lung cancer breath biomarkers based on perioperative breathomics testing: A prospective observational study. EClinicalMedicine 2022;47.
54	Hao, 2023	Hao Q-L, Wang S-W, Yu L-Q, et al. Immobilization of zeolitic imidazolate framework-90 onto modified stainless steel wire via covalent bonding for solid-phase microextraction of biomarkers in exhalation o
55	Temerdashev, 2023	Temerdashev AZ, Gashimova EM, Porkhanov VA, et al. Non-Invasive Lung Cancer Diagnostics through Metabolites in Exhaled Breath: Influence of the Disease Variability and Comorbidities. Metabolites 20
56	Li, 2017	Li W, Liu H, Xie D, et al. Lung Cancer Screening Based on Type-different Sensor Arrays. Sci Rep 2017;7.
57	Chen, 2005	Chen X, Cao MF, Li Y, et al. A study of an electronic nose for detection of lung cancer based on a virtual SAW gas sensors array and imaging recognition method. Meas Sci Technol 2005;16:1535-46.
58	Poli, 2005	Poli D, Carbognani P, Corradi M, et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 2005;6.
59	Mazzone, 2007	Mazzone PJ, Hammel J, Dweik R, et al. Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. Thorax 2007;62:565-8.
60	Dragonieri, 2009	Dragonieri S, Annema JT, Schot R, et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 2009;64:166-70.
61	D'Amico, 2010	D'Amico A, Pennazza G, Santonico M, et al. An investigation on electronic nose diagnosis of lung cancer. Lung Cancer 2010;68:170-6.
62	Mazzone, 2012	Mazzone PJ, Wang X-F, Xu Y, et al. Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer. J Thorac Oncol 2012;7:137-42.
63	Santonico, 2012	Santonico M, Lucantoni G, Pennazza G, et al. In situ detection Of lung cancer volatile fingerprints using bronchoscopic air-sampling. Lung Cancer 2012;77:46-50.
64	Wang, 2012	Wang Y, Hu Y, Wang D, et al. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines. Cancer Biomarkers 2012;11:129-37.
65	Broza, 2013	Broza YY, Kremer R, Tisch U, et al. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. Nanomed J 2013;9:15-21.
66	Bousamra, 2014	Bousamra M, II, Schumer E, Li M, et al. Quantitative analysis of exhaled carbonyl compounds distinguishes benign from malignant pulmonary disease. J Thorac Cardiovasc Surg 2014;148:1074-80.

Appendix 5 (continued)

25-36.

olites 2020;10.

r Actuat B-Chem 2020;311.

ath. Biomarkers Med 2021;15:821-9. lealthy Persons. Molecules (Basel, Switzerland)

4-31.

n of lung cancer patients. Sep Sci Plus 2023;6. s 2023;13. Appendix 5 (continued)

No.	Study, year	Citations
67	Fu, 2014	Fu X-A, Li M, Knipp RJ, et al. Noninvasive detection of lung cancer using exhaled breath. Cancer Med 2014;3:174-81.
68	Zou, 2014	Zou Y, Zhang X, Chen X, et al. Optimization of volatile markers of lung cancer to exclude interferences of non-malignant disease. Cancer Biomarkers 2014;14:371-9.
69	Capuano, 2015	Capuano R, Santonico M, Pennazza G, et al. The lung cancer breath signature: a comparative analysis of exhaled breath and air sampled from inside the lungs. Sci Rep 2015;5.
70	Li, 2015	Li M, Yang D, Brock G, et al. Breath carbonyl compounds as biomarkers of lung cancer. Lung Cancer 2015;90:92-7.
71	Schumer, 2015	Schumer EM, Trivedi JR, van Berkel V, et al. High sensitivity for lung cancer detection using analysis of exhaled carbonyl compounds. J Thorac Cardiovasc Surg 2015;150:1517-22.
72	Tan, 2016	Tan J-L, Yong Z-X, Liam C-K. Using a chemiresistor-based alkane sensor to distinguish exhaled breaths of lung cancer patients from subjects with no lung cancer. J Thorac Dis 2016;8:2772-+.
73	Callol-Sanchez, 2017	Callol-Sanchez L, Munoz-Lucas MA, Gomez-Martin O, et al. Observation of nonanoic acid and aldehydes in exhaled breath of patients with lung cancer. J Breath Res 2017;11.
74	Kistenev, 2017	Kistenev YV, Borisov AV, Kuzmin DA, et al. Exhaled air analysis using wideband wave number tuning range infrared laser photoacoustic spectroscopy. J Biomed Opt 2017;22.
75	Shlomi, 2017	Shlomi D, Abud M, Liran O, et al. Detection of Lung Cancer and EGFR Mutation by Electronic Nose System. J Thorac Oncol 2017;12:1544-51.
76	Wang, 2018	Wang M, Sheng J, Wu Q, et al. Confounding effect of benign pulmonary diseases in selecting volatile organic compounds as markers of lung cancer. J Breath Res 2018;12.
77	Zuo, 2019	Zuo W, Bai W, Gan X, et al. Detection of Lung Cancer by Analysis of Exhaled Gas Utilizing Extractive Electrospray Ionization-Mass Spectroscopy. J Biomed Nanotechnol 2019;15:633-46.
78	Binson, 2021	Binson VA, Subramoniam M, Mathew L. Noninvasive detection of COPD and Lung Cancer through breath analysis using MOS Sensor array based e-nose. Expert Rev Mol Diagn 2021;21:1223-33.
79	Binson, 2021	Binson VA, Subramoniam M, Mathew L. Detection of COPD and Lung Cancer with electronic nose using ensemble learning methods. Clin Chim Acta 2021;523:231-8.
80	Binson, 2021	Binson VA, Subramoniam M, Mathew L. Discrimination of COPD and lung cancer from controls through breath analysis using a self-developed e-nose. J Breath Res 2021;15.
81	Binson, 2021	Binson VA, Subramoniam M, Sunny Y, et al. Prediction of Pulmonary Diseases With Electronic Nose Using SVM and XGBoost. IEEE Sens J 2021;21:20886-95.
82	Chen, 2021	Chen X, Muhammad KG, Madeeha C, et al. Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection. Lung Cancer 2021;154:197-205.
83	Marzorati, 2021	Marzorati D, Mainardi L, Sedda G, et al. MOS Sensors Array for the Discrimination of Lung Cancer and At-Risk Subjects with Exhaled Breath Analysis. Chemosensors 2021;9.
84	Monedeiro, 2021	Monedeiro F, Monedeiro-Milanowski M, Ratiu I-A, et al. Needle Trap Device-GC-MS for Characterization of Lung Diseases Based on Breath VOC Profiles. Molecules (Basel, Switzerland) 2021;26.
85	Zhao, 2021	Zhao L, Qian J, Tian F, et al. A Weighted Discriminative Extreme Learning Machine Design for Lung Cancer Detection by an Electronic Nose System. IEEE Trans Instrum Meas 2021;70.
86	Rai, 2022	Rai SN, Das S, Pan J, et al. Multigroup prediction in lung cancer patients and comparative controls using signature of volatile organic compounds in breath samples. PLoS One 2022;17.
87	Wei, 2022	Wei X, Li Q, Wu Y, et al. Determination of breath isoprene in 109 suspected lung cancer patients using cavity ringdown spectroscopy. J Innovative Opt Health Sci 2022;15.
88	Smirnova, 2022	Smirnova E, Mallow C, Muschelli J, et al. Predictive performance of selected breath volatile organic carbon compounds in stage 1 lung cancer. Transl Lung Cancer Res 2022;11:1009-+.
89	Ding, 2023	Ding X, Lin G, Wang P, et al. Diagnosis of primary lung cancer and benign pulmonary nodules: a comparison of the breath test and 18F-FDG PET-CT. Front Oncol 2023;13.
-		